Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 22, 2021, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 22, 2021, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Midodrine Hydrochloride Tablets USP, 2.5 mg, 5 mg, and 10 mg".